India’s CDSCO Suspends License of Entod’s PresVu Eye Drops
Regulatory Action on Entod’s PresVu
India’s CDSCO has made the significant decision to suspend the manufacturing and marketing license for Entod Pharmaceuticals’ PresVu eye drops, a product that contains *1.25% Pilocarpine w/v*. The regulatory body cited compliance failures as primary reasons for this suspension, emphasizing the need for stringent adherence to guidelines in pharmaceutical manufacturing.
Impact on Patients and Healthcare Providers
This action poses serious implications for patients relying on PresVu for therapeutic needs. Physicians and healthcare providers must now consider alternative options for patients who utilize this medication for ocular conditions. Patient safety is paramount, necessitating an immediate shift in prescribing practices.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.